Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?

(2012) Patrick Hickey et al.   Current Neurology and Neuroscience Reports

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease

(2011) F. Stocchi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists

(2011) Nikoletta Szabó et al.   Expert Opinion on Drug Metabolism & Toxicology

Motor complications, levodopa metabolism and progression of Parkinson's disease

(2011) Thomas Müller   Expert Opinion on Drug Metabolism & Toxicology

Istradefylline for the treatment of Parkinson's disease

(2011) Ariane Park et al.   EXPERT OPINION ON PHARMACOTHERAPY

Levodopa delivery systems: advancements in delivery of the gold standard

(2010) Ndidi Ngwuluka et al.   Expert Opinion on Drug Delivery

An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats

(2010) Brigitte Spinnewyn et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives

(2010) Paul LaBeaume et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism

(2009) John D. Salamone et al.   BEHAVIOURAL BRAIN RESEARCH

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

(2008) John et al.   Frontiers in Bioscience-Landmark

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

Molecular mechanisms underlying levodopa-induced dyskinesia

(2008) Paolo Calabresi et al.   MOVEMENT DISORDERS

Placebo influences on dyskinesia in Parkinson's disease

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY